An interventional phase I/II trial aimed to evaluate the safety and efficacy of tinostamustine in OvCa. Tinostamustine shows early promise for OvCa with acceptable side effects. Tinostamustine, an innovative deacetylase inhibitor with alkylating properties, enhances accessibility to cancer cell DNA strands, inducing breaks and impeding damage repair. Anna V Tinker and her research […]...